Company profile
IDEAYA Biosciences, Inc.
NASDAQ: IDYA · Healthcare · Biotechnology
#285 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
67BFH 69DQ 65GM 64SS 64
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), balance-sheet leverage · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$225.3M
Rev growth YoY (TTM)
+3118.1%
Net income (FY)
-$113.7M
Employees
145
as of 2026-08-08
Market cap
$3.5B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$218.7M$218.7M2025
Net income-$113.7M-$113.7M2025
Operating income-$159.3M-$159.3M2025
Total assets$1.1B$1.1B2025
Liabilities$86.4M$86.4M2025
Equity$1.0B$1.0B2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Research and Development Services100%
By geography
Not disclosed.
The read
What is IDEAYA Biosciences, Inc.’s revenue?
IDEAYA Biosciences, Inc. booked $218.7M in FY2025 revenue, growing 3024% year over year — faster than 98% of Healthcare companies we track, at a -52.0% net margin.
Peers · Healthcare
Talkspace, Inc.71BPuma Biotechnology, Inc.72BAxoGen, Inc.80B+Vanda Pharmaceuticals Inc.63CTreace Medical Concepts, Inc.55CEstablishment Labs Holdings Inc.59CNeighbors
San Mateo →Key facts
CEOYujiro S. Hata
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: IDYA
Employees145
IPO date2019-05-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.